🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are increasing worldwide, with figures suggesting more than 82 million instances annually. Especially elevated rates are reported in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options presently on offer.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Gain Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the American regulatory agency in December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This milestone represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Outcomes and Worldwide Availability

Based on results published in a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This puts it on an comparable level with the current standard treatment, which uses an injection and a pill. The study included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to license and sell the drug in many developing nations.

Medical professionals on the front lines have expressed positive views. Having a single-dose, oral treatment of this kind is described as a "revolutionary step" for public health efforts. This is deemed crucial to reduce the burden of the illness for people and to halt the transmission of extremely resistant gonorrhoea globally.